nach oben

Archives of Dermatological Research

Erschienen in:

01.11.2013 | Review Article

The role of microRNAs in skin fibrosis

verfasst von: Olubukola Babalola, Andrew Mamalis, Hadar Lev-Tov, Jared Jagdeo

Erschienen in: Archives of Dermatological Research | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Fibrotic skin disorders may be debilitating and impair quality of life. There are few effective treatment options for cutaneous fibrotic diseases. In this review, we discuss our current understanding of the role of microRNAs (miRNAs) in skin fibrosis. miRNAs are a class of small, non-coding RNAs involved in skin fibrosis. These small RNAs range from 18 to 25 nucleotides in length and modify gene expression by binding to target messenger RNA (mRNA), causing degradation of the target mRNA or inhibiting the translation into proteins. We present an overview of the biogenesis, maturation and function of miRNAs. We highlight miRNA’s role in key skin fibrotic processes including: transforming growth factor-beta signaling, extracellular matrix deposition, and fibroblast proliferation and differentiation. Some miRNAs are profibrotic and their upregulation favors these processes contributing to fibrosis, while anti-fibrotic miRNAs inhibit these processes and may be reduced in fibrosis. Finally, we describe the diagnostic and therapeutic significance of miRNAs in the management of skin fibrosis. The discovery that miRNAs are detectable in serum, plasma, and other bodily fluids, and are relatively stable, suggests that miRNAs may serve as valuable biomarkers to monitor disease progression and response to treatment. In the treatment of skin fibrosis, anti-fibrotic miRNAs may be upregulated using mimics and viral vectors. Conversely, profibrotic miRNAs may be downregulated by employing anti-miRNAs, sponges, erasers and masks. We believe that miRNA-based therapies hold promise as important treatments and may transform the management of fibrotic skin diseases by physicians.

Abdullah A, Blakeney P, Hunt R, Broemeling L, Phillips L, Herndon DN, Robson MC (1994) Visible scars and self-esteem in pediatric patients with burns. J Burn Care Rehabil 15(2):164–168PubMedCrossRef

Bader A, Lorenz K, Richter A, Scheffler K, Kern L, Ebert S, Giri S, Behrens M, Dornseifer U, Macchiarini P, Machens HG (2011) Interactive role of trauma cytokines and erythropoietin and their therapeutic potential for acute and chronic wounds. Rejuvenation Res 14(1):57–66. doi:10.1089/rej.2010.1050 PubMedCrossRef

Banerjee J, Sen CK (2013) MicroRNAs in skin and wound healing. Methods Mol Biol 936:343–356. doi:10.1007/978-1-62703-083-0_26 PubMedCrossRef

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297PubMedCrossRef

Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215–233. doi:10.1016/j.cell.2009.01.002 PubMedCrossRef

Batkai S, Thum T (2012) MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep 14(1):79–87. doi:10.1007/s11906-011-0235-6 PubMedCrossRef

Bolognia JL, Jorizzo JL, Schaffer JV (2012) Dermatology, 3rd edn. Mosby, St. Louis

Bowen T, Jenkins RH, Fraser DJ (2013) MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J Pathol 229(2):274–285. doi:10.1002/path.4119 PubMedCrossRef

Brych SB, Engrav LH, Rivara FP, Ptacek JT, Lezotte DC, Esselman PC, Kowalske KJ, Gibran NS (2001) Time off work and return to work rates after burns: systematic review of the literature and a large two-center series. J Burn Care Rehabil 22(6):401–405PubMedCrossRef

10.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006. doi:10.1038/cr.2008.282 PubMedCrossRef

11.

Cheng J, Wang Y, Wang D, Wu Y (2013) Identification of collagen 1 as a post-transcriptional target of miR-29b in skin fibroblasts: therapeutic implication for scar reduction. Am J Med Sci 346(2):98–103. doi:10.1097/MAJ.0b013e318267680d PubMedCrossRef

12.

Cheng J, Yu H, Deng S, Shen G (2010) MicroRNA profiling in mid- and late-gestational fetal skin: implication for scarless wound healing. Tohoku J Exp Med 221(3):203–209PubMedCrossRef

13.

Eming SA, Krieg T, Davidson JM (2004) Gene transfer in tissue repair: status, challenges and future directions. Expert Opin Biol Ther 4(9):1373–1386. doi:10.1517/14712598.4.9.1373 PubMedCrossRef

14.

Engrav LH, Heimbach DM, Reus JL, Harnar TJ, Marvin JA (1983) Early excision and grafting vs. nonoperative treatment of burns of indeterminant depth: a randomized prospective study. J Trauma 23(11):1001–1004PubMedCrossRef

15.

Etoh M, Jinnin M, Makino K, Yamane K, Nakayama W, Aoi J, Honda N, Kajihara I, Makino T, Fukushima S, Ihn H (2013) microRNA-7 down-regulation mediates excessive collagen expression in localized scleroderma. Arch Dermatol Res 305(1):9–15. doi:10.1007/s00403-012-1287-4 PubMedCrossRef

16.

Falanga V, Iwamoto S (2012) Mechanisms of wound repair, wound healing, and wound dressing. In: Fitzpatrick’s dermatology in general medicine, 8th edn. McGraw-Hill, New York

17.

Fasanaro P, Greco S, Ivan M, Capogrossi MC, Martelli F (2010) microRNA: emerging therapeutic targets in acute ischemic diseases. Pharmacol Ther 125(1):92–104. doi:10.1016/j.pharmthera.2009.10.003 PubMedCrossRef

18.

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A (2008) Serum microRNAs are promising novel biomarkers. PLoS ONE 3(9):e3148. doi:10.1371/journal.pone.0003148 PubMedCrossRef

19.

Guo Y, Xiao L, Sun L, Liu F (2012) Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res (Acad Sci Bohemoslov) 61(4):337–346

20.

Honda N, Jinnin M, Kajihara I, Makino T, Makino K, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H (2012) TGF-beta-mediated downregulation of microRNA-196a contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J Immunol 188(7):3323–3331. doi:10.4049/jimmunol.1100876 PubMedCrossRef

21.

Honda N, Jinnin M, Kira-Etoh T, Makino K, Kajihara I, Makino T, Fukushima S, Inoue Y, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H (2013) miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin beta3. Am J Pathol 182(1):206–216. doi:10.1016/j.ajpath.2012.09.023 PubMedCrossRef

22.

Hu B, Phan SH (2013) Myofibroblasts. Curr Opin Rheumatol 25(1):71–77. doi:10.1097/BOR.0b013e32835b1352 PubMedCrossRef

23.

Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3(11):e3694. doi:10.1371/journal.pone.0003694 PubMedCrossRef

24.

Igoucheva O, Alexeev V (2009) MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 379(3):790–794. doi:10.1016/j.bbrc.2008.12.152 PubMedCrossRef

25.

Ishida M, Selaru FM (2013) miRNA-based therapeutic strategies. Curr Anesthesiol Rep 1(1):63–70. doi:10.1007/s40139-012-0004-5 PubMed

26.

Jiang X, Tsitsiou E, Herrick SE, Lindsay MA (2010) MicroRNAs and the regulation of fibrosis. FEBS J 277(9):2015–2021. doi:10.1111/j.1742-4658.2010.07632.x PubMedCrossRef

27.

Kajihara I, Jinnin M, Yamane K, Makino T, Honda N, Igata T, Masuguchi S, Fukushima S, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H (2012) Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. Am J Pathol 180(2):703–714. doi:10.1016/j.ajpath.2011.10.030 PubMedCrossRef

28.

Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, Hajjar RJ, Lebeche D (2013) Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2(2):e000078. doi:10.1161/JAHA.113.000078 PubMedCrossRef

29.

Kashiyama K, Mitsutake N, Matsuse M, Ogi T, Saenko VA, Ujifuku K, Utani A, Hirano A, Yamashita S (2012) miR-196a downregulation increases the expression of type I and III collagens in keloid fibroblasts. J Invest Dermatol 132(6):1597–1604. doi:10.1038/jid.2012.22 PubMedCrossRef

30.

Kawashita Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, Masuguchi S, Fukushima S, Inoue Y, Ihn H (2011) Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci 61(1):67–69. doi:10.1016/j.jdermsci.2010.11.007 PubMedCrossRef

31.

Kumarswamy R, Volkmann I, Thum T (2011) Regulation and function of miRNA-21 in health and disease. RNA Biol 8(5):706–713. doi:10.4161/rna.8.5.16154 PubMedCrossRef

32.

Lamouille S, Subramanyam D, Blelloch R, Derynck R (2013) Regulation of epithelial–mesenchymal and mesenchymal–epithelial transitions by microRNAs. Curr Opin Cell Biol 25(2):200–207. doi:10.1016/j.ceb.2013.01.008 PubMedCrossRef

33.

Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327(5962):198–201. doi:10.1126/science.1178178 PubMedCrossRef

34.

Li H, Yang R, Fan X, Gu T, Zhao Z, Chang D, Wang W (2012) MicroRNA array analysis of microRNAs related to systemic scleroderma. Rheumatol Int 32(2):307–313. doi:10.1007/s00296-010-1615-y PubMedCrossRef

35.

Lindow M, Kauppinen S (2012) Discovering the first microRNA-targeted drug. J Cell Biol 199(3):407–412. doi:10.1083/jcb.201208082 PubMedCrossRef

36.

Liu Y, Yang D, Xiao Z, Zhang M (2012) miRNA expression profiles in keloid tissue and corresponding normal skin tissue. Aesthet Plast Surg 36(1):193–201. doi:10.1007/s00266-011-9773-1 CrossRef

37.

Liu Z, Lu CL, Cui LP, Hu YL, Yu Q, Jiang Y, Ma T, Jiao DK, Wang D, Jia CY (2012) MicroRNA-146a modulates TGF-beta1-induced phenotypic differentiation in human dermal fibroblasts by targeting SMAD4. Arch Dermatol Res 304(3):195–202. doi:10.1007/s00403-011-1178-0 PubMedCrossRef

38.

Makino K, Jinnin M, Hirano A, Yamane K, Eto M, Kusano T, Honda N, Kajihara I, Makino T, Sakai K, Masuguchi S, Fukushima S, Ihn H (2013) The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J Immunol 190(8):3905–3915. doi:10.4049/jimmunol.1200822 PubMedCrossRef

39.

Makino K, Jinnin M, Kajihara I, Honda N, Sakai K, Masuguchi S, Fukushima S, Inoue Y, Ihn H (2012) Circulating miR-142-3p levels in patients with systemic sclerosis. Clin Exp Dermatol 37(1):34–39. doi:10.1111/j.1365-2230.2011.04158.x PubMedCrossRef

40.

Mattes J, Collison A, Plank M, Phipps S, Foster PS (2009) Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc Natl Acad Sci USA 106(44):18704–18709. doi:10.1073/pnas.0905063106 PubMedCrossRef

41.

Maurer B, Stanczyk J, Jungel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, Gay S, Distler O (2010) MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthr Rheum 62(6):1733–1743. doi:10.1002/art.27443 CrossRef

42.

Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518. doi:10.1073/pnas.0804549105 PubMedCrossRef

43.

Molnar V, Tamasi V, Bakos B, Wiener Z, Falus A (2008) Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin Cancer Biol 18(2):111–122. doi:10.1016/j.semcancer.2008.01.001 PubMedCrossRef

44.

Ning MS, Andl T (2013) Control by a hair’s breadth: the role of microRNAs in the skin. Cell Mol Life Sci 70(7):1149–1169. doi:10.1007/s00018-012-1117-z PubMedCrossRef

45.

Palmer TD, Rosman GJ, Osborne WR, Miller AD (1991) Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc Natl Acad Sci USA 88(4):1330–1334PubMedCrossRef

46.

Parapuram SK, Shi-wen X, Elliott C, Welch ID, Jones H, Baron M, Denton CP, Abraham DJ, Leask A (2011) Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. J Invest Dermatol 131(10):1996–2003. doi:10.1038/jid.2011.156 PubMedCrossRef

47.

Pastar I, Khan AA, Stojadinovic O, Lebrun EA, Medina MC, Brem H, Kirsner RS, Jimenez JJ, Leslie C, Tomic-Canic M (2012) Induction of specific microRNAs inhibits cutaneous wound healing. J Biol Chem 287(35):29324–29335. doi:10.1074/jbc.M112.382135 PubMedCrossRef

48.

Patel V, Noureddine L (2012) MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 21(4):410–416. doi:10.1097/MNH.0b013e328354e559 PubMedCrossRef

49.

Peng WJ, Tao JH, Mei B, Chen B, Li BZ, Yang GJ, Zhang Q, Yao H, Wang BX, He Q, Wang J (2012) MicroRNA-29: a potential therapeutic target for systemic sclerosis. Expert Opin Ther Targets 16(9):875–879. doi:10.1517/14728222.2012.708339 PubMedCrossRef

50.

Postlethwaite AE, Shigemitsu H, Kanangat S (2004) Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 16(6):733–738PubMedCrossRef

51.

Qu L, Liu A, Zhou L, He C, Grossman PH, Moy RL, Mi QS, Ozog D (2012) Clinical and molecular effects on mature burn scars after treatment with a fractional CO(2) laser. Lasers Surg Med 44(7):517–524. doi:10.1002/lsm.22055 PubMedCrossRef

52.

Romano C, Schepis C (2012) PTEN gene: a model for genetic diseases in dermatology. Sci World J 2012:252457. doi:10.1100/2012/252457 CrossRef

53.

Sand M, Gambichler T, Sand D, Skrygan M, Altmeyer P, Bechara FG (2009) MicroRNAs and the skin: tiny players in the body’s largest organ. J Dermatol Sci 53(3):169–175. doi:10.1016/j.jdermsci.2008.10.004 PubMedCrossRef

54.

Satoh M, Chan JY, Ceribelli A, Vazquez del-Mercado M, Chan EK (2013) Autoantibodies to Argonaute 2 (Su antigen). Adv Exp Med Biol 768:45–59. doi:10.1007/978-1-4614-5107-5_4 PubMedCrossRef

55.

Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, Yan L, Malhotra A, Vatner D, Abdellatif M (2008) MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 19(8):3272–3282. doi:10.1091/mbc.E08-02-0159 PubMedCrossRef

56.

Schlauder SM, Ahmad A, Horn TD (2009) Dicer and micro-RNAs in cutaneous disease. J Cutan Pathol 36(5):607–610. doi:10.1111/j.1600-0560.2009.01311.x PubMedCrossRef

57.

Schneider MR (2012) MicroRNAs as novel players in skin development, homeostasis and disease. Br J Dermatol 166(1):22–28. doi:10.1111/j.1365-2133.2011.10568.x PubMedCrossRef

58.

Sing T, Jinnin M, Yamane K, Honda N, Makino K, Kajihara I, Makino T, Sakai K, Masuguchi S, Fukushima S, Ihn H (2012) microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology 51(9):1550–1556. doi:10.1093/rheumatology/kes120 PubMedCrossRef

59.

Siprashvili Z, Khavari PA (2004) Lentivectors for regulated and reversible cutaneous gene delivery. Mol Ther J Am Soc Gene Ther 9(1):93–100CrossRef

60.

Sonkoly E, Stahle M, Pivarcsi A (2008) MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol 33(3):312–315. doi:10.1111/j.1365-2230.2008.02804.x PubMedCrossRef

61.

Sonkoly E, Wei T, Janson PC, Saaf A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B, Scheynius A, Stahle M, Pivarcsi A (2007) MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS ONE 2(7):e610. doi:10.1371/journal.pone.0000610 PubMedCrossRef

62.

Tan WQ, Gao ZJ, Xu JH, Yao HP (2011) Inhibiting scar formation in vitro and in vivo by adenovirus-mediated mutant Smad4: a preliminary report. Exp Dermatol 20(2):119–124. doi:10.1111/j.1600-0625.2010.01186.x PubMedCrossRef

63.

Tang O, Chen XM, Shen S, Hahn M, Pollock CA (2013) miRNA-200b represses transforming growth factor-beta1-induced EMT and fibronectin expression in kidney proximal tubular cells. Am J Physiol Renal Physiol 304(10):F1266–F1273. doi:10.1152/ajprenal.00302.2012 PubMedCrossRef

64.

Thombs BD, Haines JM, Bresnick MG, Magyar-Russell G, Fauerbach JA, Spence RJ (2007) Depression in burn reconstruction patients: symptom prevalence and association with body image dissatisfaction and physical function. Gen Hosp Psychiatry 29(1):14–20. doi:10.1016/j.genhosppsych.2006.09.002 PubMedCrossRef

65.

Thombs BD, Notes LD, Lawrence JW, Magyar-Russell G, Bresnick MG, Fauerbach JA (2008) From survival to socialization: a longitudinal study of body image in survivors of severe burn injury. J Psychosom Res 64(2):205–212. doi:10.1016/j.jpsychores.2007.09.003 PubMedCrossRef

66.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S (2008) MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224):980–984. doi:10.1038/nature07511 PubMedCrossRef

67.

Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, Calin GA (2007) miRNAs and their potential for use against cancer and other diseases. Future Oncol 3(5):521–537. doi:10.2217/14796694.3.5.521 PubMedCrossRef

68.

Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137(6):1032–1046. doi:10.1016/j.cell.2009.03.047 PubMedCrossRef

69.

Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L (2007) Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 67(7):2912–2915. doi:10.1158/0008-5472.CAN-07-0520 PubMedCrossRef

70.

Varga J (2011) Systemic sclerosis (scleroderma) and related disorders. In: Harrison’s principles of internal medicine, 18th edn. McGraw-Hill, New York

71.

Vettori S, Gay S, Distler O (2012) Role of MicroRNAs in Fibrosis. Open Rheumatol J 6:130–139. doi:10.2174/1874312901206010130 PubMedCrossRef

72.

Wang T, Feng Y, Sun H, Zhang L, Hao L, Shi C, Wang J, Li R, Ran X, Su Y, Zou Z (2012) miR-21 regulates skin wound healing by targeting multiple aspects of the healing process. Am J Pathol 181(6):1911–1920. doi:10.1016/j.ajpath.2012.08.022 PubMedCrossRef

73.

Wang Y, Huang C, Reddy Chintagari N, Bhaskaran M, Weng T, Guo Y, Xiao X, Liu L (2013) miR-375 regulates rat alveolar epithelial cell trans-differentiation by inhibiting Wnt/beta-catenin pathway. Nucleic Acids Res 41(6):3833–3844. doi:10.1093/nar/gks1460 PubMedCrossRef

74.

Wei J, Bhattacharyya S, Tourtellotte WG, Varga J (2011) Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 10(5):267–275. doi:10.1016/j.autrev.2010.09.015 PubMedCrossRef

75.

Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18(7):1028–1040. doi:10.1038/nm.2807 PubMedCrossRef

76.

Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z (2007) Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 212(2):285–292. doi:10.1002/jcp.21062 PubMedCrossRef

77.

Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O’Brien-Jenkins A, Katsaros D, Hatzigeorgiou A, Gimotty PA, Weber BL, Coukos G (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103(24):9136–9141. doi:10.1073/pnas.0508889103 PubMedCrossRef

78.

Zhu H, Li Y, Qu S, Luo H, Zhou Y, Wang Y, Zhao H, You Y, Xiao X, Zuo X (2012) MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 32(3):514–522. doi:10.1007/s10875-011-9647-y PubMedCrossRef

79.

Zhu H, Luo H, Li Y, Zhou Y, Jiang Y, Chai J, Xiao X, You Y, Zuo X (2013) MicroRNA-21 in scleroderma fibrosis and its function in TGF-beta-regulated fibrosis-related genes expression. J Clin Immunol 33(6):1100–1109. doi:10.1007/s10875-013-9896-z PubMedCrossRef

80.

Beyer C, Dees C, Distler JH (2013) Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis. Arch Dermatol Res 305:1–8PubMedCrossRef

Titel: The role of microRNAs in skin fibrosis
verfasst von: Olubukola Babalola
Andrew Mamalis
Hadar Lev-Tov
Jared Jagdeo
Publikationsdatum: 01.11.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Dermatological Research / Ausgabe 9/2013
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-013-1410-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2013

Actinic keratosis among seafarers

Expression of GLTSCR2/Pict-1 in squamous cell carcinomas of the skin

Ultraviolet light exposure stimulates HMGB1 release by keratinocytes

Stress and melanoma: increasing the evidence towards a causal basis

The reliability of counting actinic keratosis